Last reviewed · How we verify
Formulation 2 solabegron
At a glance
| Generic name | Formulation 2 solabegron |
|---|---|
| Sponsor | Velicept Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects (PHASE1)
- A Two-Part Study to Determine: Best Medication Formulation and Food Effect (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formulation 2 solabegron CI brief — competitive landscape report
- Formulation 2 solabegron updates RSS · CI watch RSS
- Velicept Therapeutics, Inc. portfolio CI